Trial Profile

ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Rett syndrome
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms EXCELLENCE
Sponsors Anavex Life Sciences

Most Recent Events

07 Feb 2024 According to an Anavex Life Sciences media release, company intend to further assess the results and discuss with the regulatory authorities next steps.
02 Jan 2024 Results of a real world evidence (RWE) feedback from Rett syndrome patients under compassionate use authorization, presented in an Anavex Life Sciences media release.
02 Jan 2024 Topline results from this trial, presented in an Anavex Life Sciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com